Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:AGTC

Applied Genetic Technologies (AGTC) Stock Price, News & Analysis

Applied Genetic Technologies logo

About Applied Genetic Technologies Stock (NASDAQ:AGTC)

Key Stats

Today's Range
$0.39
$0.39
50-Day Range
$0.37
$0.42
52-Week Range
$0.23
$2.83
Volume
N/A
Average Volume
943,490 shs
Market Capitalization
$26.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.

Receive AGTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Applied Genetic Technologies and its competitors with MarketBeat's FREE daily newsletter.

AGTC Stock News Headlines

$2 Trillion Disappears Because of Fed's Secretive New Move
$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.
Genetic Technologies Limited (GENE)
See More Headlines

AGTC Stock Analysis - Frequently Asked Questions

Applied Genetic Technologies Co. (NASDAQ:AGTC) announced its quarterly earnings results on Tuesday, November, 9th. The biotechnology company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.35) by $0.05.

Based on aggregate information from My MarketBeat watchlists, some other companies that Applied Genetic Technologies investors own include Tesla (TSLA), Meta Platforms (META), NIO (NIO), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD) and Viking Therapeutics (VKTX).

Company Calendar

Last Earnings
11/09/2021
Today
1/08/2025
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:AGTC
Fax
N/A
Employees
83
Year Founded
N/A

Profitability

Net Income
$-68,940,000.00
Pretax Margin
-21,537.54%

Debt

Sales & Book Value

Annual Sales
$320,000.00
Book Value
$0.26 per share

Miscellaneous

Free Float
64,859,000
Market Cap
$26.62 million
Optionable
Optionable
Beta
1.55

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NASDAQ:AGTC) was last updated on 1/8/2025 by MarketBeat.com Staff
From Our Partners